1. Academic Validation
  2. SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity

SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity

  • Eur J Med Chem. 2014 Apr 9:76:558-66. doi: 10.1016/j.ejmech.2014.02.051.
Giulia Nesi 1 Nicola Antonio Colabufo 2 Marialessandra Contino 3 Maria Grazia Perrone 3 Maria Digiacomo 1 Roberto Perrone 3 Annalina Lapucci 1 Marco Macchia 1 Simona Rapposelli 4
Affiliations

Affiliations

  • 1 Dipartimento di Farmacia, Università di Pisa, Via Bonanno,6 56126 Pisa, Italy.
  • 2 Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro", Via Orabona, 4, 70125 Bari, Italy. Electronic address: nicolaantonio.colabufo@uniba.it.
  • 3 Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro", Via Orabona, 4, 70125 Bari, Italy.
  • 4 Dipartimento di Farmacia, Università di Pisa, Via Bonanno,6 56126 Pisa, Italy. Electronic address: simona.rapposelli@farm.unipi.it.
Abstract

Starting from the previously developed P-gp ligands 1a and 1b (EC₅₀ = 0.25 μM and 0.65 μM, respectively), new arylmethyloxyphenyl derivatives have been synthesized as P-gp modulators in order to investigate: (i) the effect of small electron-donor groups (OMe) (5-11), (ii) the effect of the replacement of methoxy groups with an electron-withdrawal substituent (Cl) on C-ring (13) (iii) the effect induced by the replacement of C-ring with heteroaromatic cycles such as thiophene and pyrimidine (13, 15, 16), (iv) the effect induced by molecular constriction on C ring (14, 17, 18) on P-gp modulating activity. The results demonstrated that P-gp inhibition potency is strongly correlated to the number of methoxy groups in the A-ring whereas the methoxylation of C-ring seems to poorly affect P-gp activity. The best result was found for compound 10 that displays a nanomolar affinity (EC₅₀ = 7.1 nM) towards P-gp pump and, in the meantime lacks of activity against MRP1 pump.

Keywords

Arylmethyloxyphenyl compounds; Cancer; Neurodegenerative diseases; P-gp ligands.

Figures